Arboretum Ventures, a venture capital firm, led a $19m Series A round in Motif Neurotech, a neurotechnology company, with participation from KdT Ventures, Satori Neuro, Dolby Family Ventures, re.Mind Capital, Max Hodak, Divergent Capital, TMC Innovation, PsyMed Ventures, Empath Ventures and Capital Factory. “Minimally-invasive bioelectronics are the future of mental health treatment. 30% of patients with depression don’t respond to two or more medications, and there is a significant need for additional treatment options that are effective and easily accessible. The DOT microstimulator is a wireless, battery-free device designed to be implanted in a 20-minute outpatient procedure with the capability for at-home therapy. This round of financing will allow us to bring this technology into a clinical study for patients with TRD,” Jacob Robinson, Motif Neurotech CEO & Founder.